|View printer-friendly version|
In the study titled “Human embryonic stem cell-derived neural crest cells capable of expressing markers of osteochondral or meningeal–choroid plexus differentiation,”
“To our knowledge, this is the first report of the isolation of these important cell types,” said
Authors of today’s publication included
Asterias Biotherapeutics, Inc.is a new subsidiary which has acquired the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. OncoCyte Corporationis developing products and technologies to diagnose and treat cancer. Cell Cure Neurosciences Ltd.(“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc.(“LifeMap Sciences”) markets, sells and distributes GeneCards®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery™ database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. ES Cell International Pte Ltd., a Singaporeprivate limited company, developed clinical and research grade hES cell lines and plans to market those cell lines and other BioTimeresearch products in over-seas markets as part of BioTime’s ESI BIO Division. BioTime Asia, Limited, a Hong Kongcompany, may offer and sell products for research use for BioTime’s ESI BIO Division. OrthoCyte Corporationis developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc.is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.
To receive ongoing
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for